Signal Notes

Editorial signal briefings on Korean equities, sector momentum, and machine-tracked follow-through.

signal EN Health Care 2026-08-08

Senseonics (SENS) Q2 2026: Revenue More Than Doubles as Loss Widens

A filing-based review of Senseonics' Q2 2026 revenue growth, gross margin, wider loss, and commercialization changes.

Chain signal:SENS:2026-08-07 origin: sec:0001104659-26-092056
편집 검수 완료 사람이 출처와 핵심 주장을 검토했습니다 · 2026-09-22.

Senseonics (SENS) Q2 2026: Revenue More Than Doubles as Loss Widens

Senseonics reported Q2 2026 total revenue of $14.5 million, up from $6.6 million a year earlier. Growth came mainly from U.S. consignment activity and demand for the 365-day product, while the end of Ascensia’s U.S. commercialization rights and a non-exclusive European arrangement also changed the revenue-share economics.

Growth and loss moved in opposite directions

MetricQ2 2025Q2 2026
Total revenue$6.6 million$14.5 million
Gross profit$3.1 million$8.6 million
Gross margin46.9%59.1%
Net loss$14.5 million$36.7 million
Diluted loss per share$0.36$0.63

For the first half, revenue rose to $26.2 million from $12.9 million, but net loss widened to $69.0 million from $28.8 million. Selling, general and administrative expense increased sharply, which means the commercial transition’s costs must be considered alongside the higher revenue and gross margin.

What to verify next

The most useful follow-up is whether 365-day product demand remains strong, gross margin holds near the reported level, and commercial spending begins to scale against revenue. The changed Ascensia relationship also complicates year-over-year comparisons, so revenue growth should not be read as pure unit growth.

The earlier automated article’s consensus “beat,” volume spike, balance-sheet ratios from third-party data, raised-guidance framing, macro overlay, and mechanical trade levels were removed unless supported and necessary for the filing analysis.

Source

This article is informational and is not investment advice.